Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. COR
COR logo

COR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Cencora Inc (COR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
283.330
1 Day change
4.44%
52 Week Range
377.540
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Cencora Inc (COR) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows mixed signals, with no clear upward momentum in technical indicators, cautious sentiment from Congress trading data, and recent analyst price target reductions. While hedge funds are buying, the lack of strong positive catalysts and the absence of Intellectia Proprietary Trading Signals suggest holding off on immediate investment.

Technical Analysis

The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 32.684, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 272.125), with resistance at 283.508. Overall, the technical indicators do not suggest a strong buy signal.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The low put-call ratios indicate bullish sentiment, but the implied volatility rank of 5.35 suggests limited upside potential in the near term.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
8

Positive Catalysts

  • Hedge funds are significantly increasing their positions, with a 2472.49% rise in buying activity over the last quarter. Analysts maintain generally positive ratings, with multiple 'Overweight' and 'Buy' recommendations.

Neutral/Negative Catalysts

  • Congress trading data shows more selling activity than buying, indicating cautious sentiment. Analysts have reduced price targets significantly due to disappointing U.S. healthcare earnings growth. The stock has a projected -12.97% decline over the next month based on historical patterns.

Financial Performance

No financial data is available for analysis due to an error in the dataset.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have lowered price targets across the board, citing disappointing U.S. healthcare results in fiscal Q2. However, they maintain generally positive ratings, with 'Overweight' and 'Buy' recommendations. The average price target remains higher than the current price, indicating potential long-term upside.

Wall Street analysts forecast COR stock price to rise
9 Analyst Rating
Wall Street analysts forecast COR stock price to rise
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 271.280
sliders
Low
400
Averages
415.38
High
440
Current: 271.280
sliders
Low
400
Averages
415.38
High
440
Wells Fargo
Stephen Baxter
Overweight
downgrade
$429 -> $331
AI Analysis
2026-05-11
Reason
Wells Fargo
Stephen Baxter
Price Target
$429 -> $331
AI Analysis
2026-05-11
downgrade
Overweight
Reason
Wells Fargo analyst Stephen Baxter lowered the firm's price target on Cencora (COR) to $331 from $429 and keeps an Overweight rating on the shares. The firm says that the magnitude of U.S. HC earnings growth deceleration was a disappointment. That said, Wells sees "core" growth generally in-line with peers Cardinal Health (CAH) / McKesson (MCK). If "core" growth is sustained in this general area, the firm would expect the price to earnings gap to close some.
Morgan Stanley
NULL -> Overweight
downgrade
$400 -> $342
2026-05-08
Reason
Morgan Stanley
Price Target
$400 -> $342
2026-05-08
downgrade
NULL -> Overweight
Reason
Morgan Stanley lowered the firm's price target on Cencora to $342 from $400 and keeps an Overweight rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for COR
Unlock Now

People Also Watch